Nurix Therapeutics, Inc.

NRIX

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001549595

SEC filings (opens in a new tab)

In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 211 institutions reported holding it in 13F filings for Q2 2026, worth $2.84B in total; ARK Invest is the only superinvestor holding it.

Q3 2021 vs. Q2 2021

How the institutions holding Nurix Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021 All holders in Q2 2021

13F holders of NRIX: Q2 2021 compared with Q3 2021
Measure	Q2 2021	Of which not filed for Q3 2021	Q3 2021	Change
Holders	104	1	113	+10
Shares	39.5M	676.9K	39.5M	+627.9K (+1.6%)
Value	$1.05B	$18.0M	$1.18B	+$153.0M (+14.8%)

1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (25)

Institutions that held Nurix Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to NRIX in Q3 2021
Institution	Shares	Value	% of portfolio
Pictet Asset Management SA	927,550	$27.8M	0.03%
WestHill Financial Advisors, Inc.	283,333	$8.49M	2.62%
Soleus Capital Management, L.P.	263,900	$7.91M	1.23%
Bank of Montreal	164,255	$5.37M	0.00%
Woodline Partners LP	137,401	$4.12M	0.07%
Alyeska Investment Group, L.P.	115,000	$3.44M	0.04%
Mission Creek Capital Partners, Inc.	39,764	$1.19M	0.22%
Susquehanna Fundamental Investments, LLC	31,442	$942.0K	0.02%
Mariner, LLC	29,000	$869.0K	0.00%
Standard Life Aberdeen plc	19,085	$572.0K	0.00%
Mass General Brigham, Inc	15,904	$476.0K	0.13%
Blackstone Group Inc.	14,188	$425.0K	0.00%
Winton Group Ltd	13,659	$409.0K	0.02%
Algert Global LLC	13,513	$405.0K	0.05%
ExodusPoint Capital Management, LP	10,747	$322.0K	0.00%
Walleye Capital LLC	10,546	$316.0K	0.01%
Blueshift Asset Management, LLC	8,617	$258.0K	0.01%
Natixis	8,496	$255.0K	0.00%
American Financial Group Inc	7,442	$223.0K	0.06%
State Board of Administration of Florida Retirement System	6,808	$204.0K	0.00%
Guggenheim Capital LLC	6,702	$201.0K	0.00%
Fiduciary Trust Co	6,680	$200.0K	0.00%
Amundi	614	$18.0K	0.00%
Migdal Insurance & Financial Holdings Ltd.	595	$18.0K	0.00%
Group One Trading, L.P.	100	$3.00K	0.00%

Sold out (15)

Institutions that held Nurix Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of NRIX in Q3 2021
Institution	Shares, Q2 2021	Value, Q2 2021
Sphera Funds Management Ltd.	244,157	$6.48M
Ameriprise Financial Inc	224,686	$5.96M
Euclidean Capital LLC	154,426	$4.10M
Voloridge Investment Management, LLC	106,320	$2.82M
Balyasny Asset Management LLC	78,527	$2.08M
Raymond James Financial Services Advisors, Inc.	43,826	$1.16M
Cambridge Investment Research Advisors, Inc.	29,000	$769.0K
D. E. Shaw & Co., Inc.	24,012	$637.0K
Cubist Systematic Strategies, LLC	12,663	$336.0K
Squarepoint Ops LLC	10,558	$280.0K
Hershey Trust Co	8,807	$234.0K
Virtu Financial LLC	7,574	$201.0K
Chescapmanager LLC	7,442	$197.0K
Russell Investments Group, Ltd.	5,749	$152.0K
Point72 Hong Kong Ltd	116	$3.00K

Not filed for Q3 2021 yet (1)

Institutions that held Nurix Therapeutics, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NRIX in Q2 2021 that haven't filed for Q3 2021
Institution	Shares, Q2 2021	Value, Q2 2021
Pictet Asset Management Ltd	676,887	$18.0M